Table 3 Bivariate analysis of risk factors related to inflammation and hepatic fibrosis classified according to the METAVIR scale
Evaluation of polymorphisms | A0-A1 | A2-A3 | CG | P | Odds ratio | CI 95% | F0-F1 | F2 | F3-F4 | CG | P | Odds ratio | CI 95% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NGF | |||||||||||||
-198C > T | |||||||||||||
CC | 14 (20.59) | 3 (08.82) | 94 (31.33) | 0.01d | 1.0g | – | 11 (22.45) | 2 (07.69) | 4 (14.81) | 94 (31.33) | 0.04d | 9.0g | – |
CT | 41 (60.29) | 19 (55.88) | 152 (50.67) | 26 (53.06) | 19 (73.08) | 15 (55.56) | 152 (50.67) | ||||||
TT | 13 (19.12) | 12 (35.29) | 54 (18.00) | 12 (24.49) | 5 (19.23) | 8 (29.63) | 54 (18.00) | ||||||
C | 69 (50.74) | 25 (36.76) | 340 (56.67) | 0.00a | 48 (48.98) | 23 (44.23) | 23 (42.59) | 340 (56.67) | 0.06 a | ||||
T | 67 (49.26) | 43 (63.24) | 260 (43.33) | 50 (51.02) | 29 (55.77) | 31 (57.41) | 260 (43.33) | ||||||
HAPLOTYPES | |||||||||||||
ArgValAlaAla+/+ | 29 (44.62) | 11 (35.48) | 100 (33.33) | 0.00d | 1.4g | – | 17 (37.78) | 11 (44.00) | 12 (46.15) | 100 (33.33) | 0.00c | 1.1g | – |
ArgValAlaAla ArgValValAla | 28 (43.08) | 14 (45.16) | 110 (36.73) | 22 (48.89) | 12 (48.00) | 8 (30.77) | 110 (36.73) | ||||||
ArgValValAla+/+ | 4 (06.15) | 5 (16.13) | 14 (04.76) | 3 (06.67) | 1 (04.00) | 5 (19.23) | 14 (04.76) | ||||||
Other haplotypes | 4 (06.15) | 1 (03,23) | 76 (25.17) | 3 (06.67) | 1 (04.00) | 1 (03.85) | 76 (25.17) | ||||||
Ser205Leu | |||||||||||||
SerSer | 59 (89.39) | 30 (90.91) | 264 (88.00) | 0.85d | 45 (93.75) | 25 (96.15) | 19 (76.00) | 264 (88.00) | 0.70d | ||||
SerLeu | 6 (09.09) | 3 (10.61) | 35 (11.67) | 3 (06.25) | 5 (16.13) | 1 (24.00) | 35 (11.67) | ||||||
LeuLeu | 1 (01.52) | 0 | 1 (00.33) | 0 | 1 (03.23) | 0 | 1 (00.33) | ||||||
Ser | 124 (93.94) | 63 (95.45) | 563 (93.83) | 0.87a | 93 (96.88) | 55 (88.71) | 39 (97.50) | 563 (93.83) | 0.17d | ||||
Leu | 8 (06.06) | 3 (04.55) | 37 (06.17) | 3 (03.12) | 7 (11.29) | 1 (02.50) | 37 (06.17) | ||||||